Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells

Leukemia

Volumn 21, Issue 12, 2007, Pages 2411-2419

  Meers, S ^a   Kasran, A ^a   Boon, L ^b   Lemmens, J ^c   Ravoet, C ^d   Boogaerts, M ^a   Verhoef, G ^a   Verfaillie, C ^a   Delforge, M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b PanGenetics BV   (Netherlands)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; TRISOMY 8;

EID: 36348986647     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404940     Document Type: Article

References (38)

1. Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J 2003; 4: 303-309.
2. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322.
3. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit hemopoiesis in long-term cultures in patients with myelodysplastic syndromes. Exp Hematol 2002; 30: 1405-1411.
4. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst JJ, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: Evidence for an autoimmune process. Leuk Res 2001; 25: 1075-1083.
5. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841-851.
6. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006; 108: 2632-2641.
7. Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 2007; 21: 659-667.
8. Jonasova A, Neuwirtova R, Cermak J. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998; 200: 304-309.
9. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin formyelodysplastic syndrome? Br J Haematol 1988; 68 139-140.
10. Biesma D, van den Tweel J, Verdonck L. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79: 1548-1551.
11. Molldrem J, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
12. Molldrem J, Rivera M, Bahceci E. Treatment of bone marrow failure of myelodysplastic syndrome with antithymocyte globulin. Ann Intern Med 2002; 137: 156-163.
13. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667-670.
14. Barrett J, Sloand E, Young N. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment. Haematologica 2006; 91: 583-584.
15. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
16. Parker J, Mufti G. The myelodysplastic syndromes: A matter of life or death. Acta Haematologica 2004; 111: 78-99.
17. Visani G, Zauli G, Tosi P, Fogli M, Cenacchi A, Finelli C et al. Impairment of GM-CSF production in myelodysplastic syndromes. Br J Haematol 1993; 84: 227-231.
18. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135.
19. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
20. Harigai M, Hara M, Nakazawa S, Fukasawa C, Ohta S, Sugiura T et al. Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: A novel mechanism of activation of synoviocytes. J Rheumatol 1999; 26: 1035-1043.
21. Sekine C, Yagita H, Miyasaka N, Okumura K. Expression and function of CD40 in rheumatoid arthritis synovium. J Rheumatol 1998; 25: 1048-1053.
22. Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005; 22: 111-122.
23. Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm Bowel Dis 2006; 12: 1013-1024.
24. t Hart BA, Blezer EL, Brok HP, Boon L, de Boer M, Bauer J et al. Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 2005; 163: 31-39.
25. Carayanniotis G, Masters SR, Noelle RJ. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997; 90: 421-426.
26. Companjen AR, van der Wel LI, Boon L, Prens EP, Laman JD. CD40 ligation-induced cytokine production in human skin explants is partly mediated via IL-1. Int Immunol. 2002; 14: 669-676.
27. Benveniste EN, Nguyen VT, Wesemann DR. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun 2004; 18: 7-12.
28. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
29. Eisen HN. Specificity and degeneracy in antigen recognition: Yin and yang in the immune system. Annu Rev Immunol 2001; 19: 1-21.
30. Burger D, Molnarfi N, Gruaz L, Dayer JM. Differential induction of IL-1beta and TNF by CD40 ligand or cellular contact with stimulated T cells depends on the maturation stage of human monocytes. J Immunol 2004; 173: 1292-1297.
31. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270-1277.
32. Sugimoto K, Galle C, Preiser JC, Creteur J, Vincent JL, Pradier O. Monocyte CD40 expression in severe sepsis. Shock 2003; 19: 24-27.
33. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-3027.
34. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications. Cancer Res 2004; 64: 2846-2852.
35. Tai Y-T, Li X-F, Cadey L, Coffey R, Breitkreutz I, Bae J et al. Immunomodulatory drug lenalidomide (CC-5013, iMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical Implications. Cancer Res 2005; 65: 11712-11720.
36. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333-350.
37. Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003; 121: 592-596.
38. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM et al. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology 2006; 118: 261-270.